Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Cardiovascular drugs and therapy - 38(2024), 2 vom: 20. Jan., Seite 391-392 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tse, Gary [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 |
|---|
| doi: |
10.1007/s10557-024-07550-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055249264 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055249264 | ||
| 003 | DE-627 | ||
| 005 | 20240323064717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10557-024-07550-8 |2 doi | |
| 035 | |a (DE-627)SPR055249264 | ||
| 035 | |a (SPR)s10557-024-07550-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Tse, Gary |e verfasserin |0 (orcid)0000-0001-5510-1253 |4 aut | |
| 245 | 1 | 0 | |a Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 | ||
| 700 | 1 | |a Lee, Sharen |4 aut | |
| 700 | 1 | |a Liu, Tong |4 aut | |
| 700 | 1 | |a Zhou, Jiandong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular drugs and therapy |d Springer US, 1987 |g 38(2024), 2 vom: 20. Jan., Seite 391-392 |w (DE-627)SPR011281340 |w (DE-600)2003553-6 |x 1573-7241 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:20 |g month:01 |g pages:391-392 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10557-024-07550-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 20 |c 01 |h 391-392 | ||